Prophylaxis for Venous Thromboembolic Events in Elective Total Hip and Total Knee Arthroplasty

Curr Pharm Des. 2022;28(10):771-777. doi: 10.2174/1381612828666220418090928.

Abstract

Venous thromboembolism (VTE) is a serious complication after major orthopaedic operations, such as a total hip (THA) and knee (TKA) arthroplasty. Therefore, perioperative VTE prophylaxis is recommended; a multitude of modern options are available, including both pharmacologic (aspirin, unfractionated and lowmolecular- weight heparin, vitamin K antagonists, and novel oral anticoagulants) and/or mechanical interventions (early mobilization, graduated compression stockings, intermittent pneumatic compression devices, and venous foot pumps). However, because of the abundance of these possibilities, it is crucial to understand the benefits and drawbacks of each VTE prophylaxis option to ensure that the optimal treatment plan is developed for each patient. The American College of Chest Physicians (AACP) and the American Academy of Orthopaedic Surgeons (AAOS) have both published individual guidelines on VTE prophylaxis regimens, alongside numerous studies evaluating the efficacy and outcomes of the different prophylaxis modalities. The purpose of this review is to provide a summary of the evidence on VTE prophylaxis after elective total hip and knee arthroplasty based on current guidelines and highlight the major concerns and potential complications.

Keywords: Pharmaceutical prophylaxis; hematoma; oral anticoagulants; total hip and total knee arthroplasty; venous thromboembolism; vitamin K antagonists.

Publication types

  • Review

MeSH terms

  • Anticoagulants / therapeutic use
  • Arthroplasty, Replacement, Hip* / adverse effects
  • Arthroplasty, Replacement, Knee* / adverse effects
  • Humans
  • Postoperative Complications / drug therapy
  • Postoperative Complications / prevention & control
  • United States
  • Venous Thromboembolism* / etiology
  • Venous Thromboembolism* / prevention & control
  • Venous Thrombosis* / prevention & control

Substances

  • Anticoagulants